Comparative Pharmacology
Head-to-head clinical analysis: FINTEPLA versus NEURONTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FINTEPLA versus NEURONTIN.
FINTEPLA vs NEURONTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fenfluramine (FINTEPLA) is a serotonin-releasing agent and serotonin receptor agonist, primarily at 5-HT2 receptors. It also acts as a sigma-1 receptor agonist and modulates GABAergic and glutamatergic transmission.
Gabapentin binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing neurotransmitter release, particularly glutamate, norepinephrine, and substance P. It does not interact with GABA receptors.
0.1-0.2 mg/kg twice daily (oral), with a maximum of 16 mg/day for patients weighing ≥50 kg; for patients <50 kg, maximum 8 mg/day.
300 mg orally once daily on day 1, 300 mg twice daily on day 2, then 300 mg three times daily on day 3; titrate up to effective dose, usual maintenance 300-600 mg three times daily, maximum 3600 mg/day.
None Documented
None Documented
Terminal elimination half-life approximately 9 hours in adults; at steady state, accumulation minimal with twice-daily dosing.
Terminal elimination half-life is 5–7 hours in patients with normal renal function; in elderly or those with renal impairment, half-life may be prolonged up to 132 hours; requires dose adjustment for creatinine clearance <60 mL/min.
Renal: 65% as unchanged drug; Fecal: 29% primarily as metabolites; Biliary: negligible.
Renal elimination as unchanged drug: >90%; 0.3% is excreted in feces; biliary elimination is negligible.
Category C
Category C
Antiepileptic
Antiepileptic